GL701 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus3

49. Systemic lupus erythematosus


Clinical trials : 993 Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00082511
(ClinicalTrials.gov)
July 200311/5/2004GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With GlucocorticoidsA Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With GlucocorticoidsSystemic Lupus ErythematosusDrug: Prasterone (GL701)Genelabs TechnologiesNULLCompleted18 YearsN/AFemale114Phase 3United States;Mexico
2NCT00053560
(ClinicalTrials.gov)
December 200230/1/2003To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With GlucocorticoidsA Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With GlucocorticoidsLupusDrug: Prasterone (GL701)Genelabs TechnologiesNULLActive, not recruiting18 YearsN/AFemale155Phase 3United States;Mexico
3NCT00037128
(ClinicalTrials.gov)
March 199816/5/2002Study of GL701 in Men With Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: GL701Genelabs TechnologiesNULLActive, not recruiting18 YearsN/AMale40Phase 3United States